Hyperkalemia is defined as a serum potassium concentration >5.0 mEq/L in adults (>5.5 mEq/L in children), with severe hyperkalemia (≥6.5 mEq/L) carrying risk of life-threatening cardiac arrhythmias and cardiac arrest. [1-2] Prevalence in the general population is ~3.3%, rising to 18% in patients with CKD. [2] The following is a clinically organized summary for emergency and primary care management.
The following algorithm from the AAFP outlines a practical approach to evaluation and management:
1. History
- Onset and timeline: Acute vs. chronic elevation; recent medication changes, dietary indiscretions, missed dialysis sessions
- Symptom characterization: Muscle weakness, fatigue, paresthesias, palpitations, nausea [3-4]
- Triggers: New medications (ACEi/ARB, K-sparing diuretics, NSAIDs, trimethoprim, calcineurin inhibitors), potassium supplements, salt substitutes, blood transfusions [2][5]
- Associated symptoms: Oliguria/anuria, diarrhea, recent trauma/crush injury, recent chemotherapy (tumor lysis syndrome)
- Important negatives: Confirm no tourniquet use or fist clenching during blood draw (pseudohyperkalemia); no hemolyzed sample [2]
2. Alarm Features
- K⁺ ≥6.5 mEq/L regardless of symptoms [5]
- ECG changes: Peaked T waves, loss of P waves, PR prolongation, QRS widening, sine wave pattern, bradycardia, junctional rhythm [1][6]
- Muscle weakness or paralysis, especially ascending [3]
- Rapid rise in potassium (even if absolute level is moderate) — the rate of change may be more dangerous than the absolute level [7]
- Cardiac arrest rhythms: VF, VT, PEA, asystole [1]
- Bradycardia (RR 12.3 for serious adverse event), prolonged QRS (RR 4.7), junctional rhythm (RR 7.5) are the ECG findings most predictive of serious adverse events within 6 hours [2]
3. Medications
Causative medications (review and hold/adjust as appropriate):
- ACE inhibitors, ARBs, direct renin inhibitors
- Potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene)
- NSAIDs and COX-2 inhibitors (COX-2 inhibitors carry greater risk) [2]
- Trimethoprim, calcineurin inhibitors (tacrolimus, cyclosporine)
- Beta-blockers, digoxin, heparin/LMWH
- Potassium supplements, salt substitutes [5][8]
Treatment medications (see Treatment Plan for dosing)
- IV calcium gluconate or calcium chloride (membrane stabilization)
- Regular insulin + dextrose (intracellular shift)
- Nebulized albuterol/salbutamol (intracellular shift, synergistic with insulin)
- Sodium bicarbonate (only if concurrent metabolic acidosis) [9]
- Loop diuretics (potassium excretion)
- Newer potassium binders: sodium zirconium cyclosilicate (Lokelma) and patiromer (Veltassa) [2][10]
- Sodium polystyrene sulfonate (Kayexalate) is no longer recommended due to questionable efficacy and GI adverse events [9]
Contraindicated medications: Avoid potassium-containing IV fluids (e.g., LR), succinylcholine in known hyperkalemia, and do not mix sodium bicarbonate and calcium in the same IV line. [11]
4. Diet
- Acute: Eliminate all oral and IV potassium sources immediately [11]
- Chronic management: Restrict dietary potassium to <2.4 g/day in patients with CKD stage ≥3 [12]
- Avoid: Salt substitutes (often contain KCl), high-potassium processed foods [13-14]
- Nuanced approach: KDIGO and recent evidence suggest focusing on reducing nonplant sources of potassium rather than blanket restriction of all K⁺-rich foods, as plant-based K⁺ sources have lower bioavailability and may confer cardiovascular benefit [15]
- Counsel on hidden sources: enteral feeds, parenteral nutrition, herbal supplements (alfalfa, dandelion, nettle, Lily of the Valley) [2][8]
- Ensure adequate hydration and avoid constipation (colonic K⁺ excretion is impaired with constipation) [5][14]
5. Review of Systems
- Cardiovascular: Palpitations, chest pain, syncope, presyncope
- Neuromuscular: Weakness (especially proximal/ascending), paresthesias, cramping, fatigue
- GI: Nausea, vomiting, abdominal pain, ileus, diarrhea [3]
- Renal: Urine output changes, hematuria, foamy urine
- Respiratory: Dyspnea (respiratory muscle weakness in severe cases)
- Endocrine: Polyuria/polydipsia (diabetes, adrenal insufficiency)
6. Collateral History and Family History
- Dialysis schedule: Missed sessions, adequacy of dialysis
- Medication compliance: Recent changes, OTC supplements, herbal products
- Family history: Hereditary conditions — familial hyperkalemic periodic paralysis, pseudohypoaldosteronism, congenital adrenal hyperplasia
- Social context: Access to dialysis, dietary habits, food insecurity (may affect ability to follow low-K⁺ diet)
7. Risk Factors
- CKD/ESRD (most significant risk factor) [16]
- Diabetes mellitus (hyporeninemic hypoaldosteronism, insulin deficiency) [5][16]
- Heart failure (RAAS inhibitor use, cardiorenal syndrome) [16]
- Adrenal insufficiency / hypoaldosteronism
- Medications: RAAS inhibitors, K-sparing diuretics, NSAIDs, trimethoprim [2][5]
- Acute tissue breakdown: Rhabdomyolysis, crush injury, burns, tumor lysis syndrome, massive hemolysis [1-2]
- Metabolic acidosis (transcellular shift)
- Constipation (impairs colonic K⁺ excretion) [5]
- Volume depletion (reduces renal K⁺ excretion)
8. Differential Diagnosis
- Pseudohyperkalemia (hemolyzed sample, prolonged tourniquet, fist clenching, thrombocytosis, leukocytosis) — always exclude first [2]
- Renal failure (acute or chronic) — most common true cause
- Medication-induced hyperkalemia
- Adrenal insufficiency / Addison's disease
- Diabetic ketoacidosis (insulin deficiency + acidosis)
- Rhabdomyolysis / crush syndrome
- Tumor lysis syndrome [11][17]
- Massive blood transfusion
- Type IV renal tubular acidosis
- Hyperkalemic periodic paralysis (rare)
9. Past Medical History
- CKD stage and baseline creatinine/GFR
- Diabetes mellitus (type, control, insulin use)
- Heart failure (EF, RAAS inhibitor use)
- Prior episodes of hyperkalemia and treatments used
- Dialysis history (modality, schedule, access)
- Adrenal disease
- History of rhabdomyolysis or tumor lysis
- Transplant history (calcineurin inhibitor use)
10. Physical Exam
- Vitals: Bradycardia (ominous sign), hypotension
- Cardiac: Irregular rhythm, bradycardia
- Neuromuscular: Decreased deep tendon reflexes, proximal muscle weakness, flaccid paralysis (ascending pattern)
- Respiratory: Assess respiratory effort (severe cases → respiratory muscle weakness)
- Volume status: JVD, edema, skin turgor (assess for volume overload vs. depletion)
- Abdominal: Distension, decreased bowel sounds (ileus)
- Skin: Signs of crush injury, burns, compartment syndrome
- Dialysis access: Assess fistula/graft patency if applicable
11. Lab Studies
- Stat BMP/CMP: Serum potassium (repeat if unexpected or discordant with clinical picture — draw without tourniquet, unclenched fist) [2]
- BUN/Creatinine, GFR: Assess renal function
- Glucose: Baseline before insulin therapy; monitor q1h after insulin to detect hypoglycemia [9]
- Venous or arterial blood gas: Assess for metabolic acidosis
- Magnesium, calcium, phosphorus: Concurrent electrolyte abnormalities
- CBC: Leukocytosis/thrombocytosis (pseudohyperkalemia); hemolysis
- CK: If rhabdomyolysis suspected
- Uric acid, LDH, phosphorus: If tumor lysis syndrome suspected [17]
- Digoxin level: If on digoxin (IV calcium relatively contraindicated in dig toxicity — use cautiously)
- Cortisol/ACTH: If adrenal insufficiency suspected
- Urine potassium, urine electrolytes: Transtubular potassium gradient (TTKG) to differentiate renal vs. extrarenal causes
12. Imaging
- Imaging is generally not the primary diagnostic tool for hyperkalemia
- Renal ultrasound: If new renal failure is identified — assess for obstruction, kidney size
- Chest X-ray: If volume overload, pulmonary edema, or heart failure suspected
- CT abdomen: If rhabdomyolysis with compartment syndrome or adrenal pathology suspected
13. Special Tests
Severity classification (KDIGO): [5]
- Mild: 5.0–5.9 mEq/L without ECG changes
- Moderate: 5.0–5.9 mEq/L with ECG changes, or 6.0–6.4 mEq/L without ECG changes
- Severe: 6.0–6.4 mEq/L with ECG changes, or ≥6.5 mEq/L regardless of ECG
- Point-of-care iSTAT/blood gas potassium: Rapid bedside confirmation (whole blood K⁺ may differ slightly from serum)
- Transtubular potassium gradient (TTKG): Helps differentiate renal vs. extrarenal causes (though clinical utility is debated)
- Point-of-care ultrasound: Cardiac function, IVC assessment for volume status
14. ECG
ECG should be obtained in all patients with suspected or confirmed hyperkalemia, though ECG changes have low sensitivity and do not reliably correlate with serum K⁺ levels. [2]
Progressive ECG changes: [1][3][6]
- K⁺ 5.5–6.5: Peaked, narrow-based T waves (earliest finding)
- K⁺ 6.5–7.5: PR prolongation, P wave flattening/loss
- K⁺ 7.0–8.0: QRS widening
- K⁺ >8.0: Sine wave pattern, merging of widened QRS with T wave
- K⁺ >10: VF, asystole, PEA
Key pearl: The rate of potassium rise may be more important than the absolute level in predicting ECG changes. Patients with lower baseline K⁺ who experience a rapid rise are at higher risk of ECG abnormalities. [7]
The following algorithm provides an ECG-directed treatment framework:
15. Assessment
- Severity stratification drives management: mild cases may be managed with medication adjustment and dietary counseling; moderate-to-severe cases require emergent intervention [5]
- Hyperkalemia is associated with increased mortality in a U-shaped relationship — optimal serum K⁺ is 4.0–5.0 mEq/L [2]
- Patients with CKD may tolerate higher K⁺ levels due to adaptive mechanisms, but this does not eliminate risk [5]
- Atypical presentations: Frequently asymptomatic until severe; may present as unexplained bradycardia, weakness, or cardiac arrest [3]
- Complications: Fatal arrhythmias (VF, asystole), respiratory failure from muscle paralysis, metabolic acidosis (hyperkalemia can cause type IV RTA) [16]
16. Treatment Plan
Treatment follows a three-tier approach: membrane stabilization → intracellular shift → potassium elimination. [2][9][19]
Tier 1 — Cardiac Membrane Stabilization (for ECG changes or K⁺ ≥6.5):
- Calcium gluconate 10%: 1,000–2,000 mg (10–20 mL) IV over 2–5 minutes; may repeat in 5–10 minutes if ECG changes persist [2][19]
- Calcium chloride 10%: 10 mL IV (preferred in cardiac arrest — 3× more elemental calcium; requires central line ideally) [19]
- Onset: 1–3 minutes; duration: 30–60 minutes
- Caution with digoxin toxicity: Administer calcium slowly over 20–30 minutes if digitalized
Tier 2 — Intracellular Potassium Shift
- Regular insulin 10 units IV + dextrose 25 g (D50 50 mL) IV — lowers K⁺ by 0.6–1.2 mEq/L at 1 hour [2]
- If glucose >250 mg/dL, insulin may be given without dextrose
- Monitor glucose q1h for 4–6 hours — hypoglycemia risk is significant, especially in non-diabetic patients [9]
- Nebulized albuterol 10–20 mg — lowers K⁺ by ~0.6 mEq/L within 30 minutes; synergistic with insulin [2][4]
- Sodium bicarbonate: 150 mEq in 1 L D5W over 2–4 hours — only if concurrent metabolic acidosis; avoid in ESRD; do not use normal saline as diluent [2][9]
Tier 3 — Potassium Elimination
- Loop diuretics (furosemide): Effective if patient has adequate renal function and urine output [9]
- Sodium zirconium cyclosilicate (Lokelma): 10 g PO TID × 48 hours for acute management [2][10]
- Patiromer (Veltassa): 8.4 g PO daily, titrate to 16.8–25.2 g/day (better suited for chronic management) [2]
- Hemodialysis: Definitive treatment for refractory hyperkalemia, ESRD, or ongoing K⁺ release [9][19]
17. Disposition
Admit (telemetry or ICU): [5]
- K⁺ ≥6.5 mEq/L
- Any ECG changes attributable to hyperkalemia
- Symptomatic hyperkalemia (weakness, arrhythmia)
- Refractory to initial treatment
- Requiring emergent dialysis
- Ongoing source of K⁺ release (rhabdomyolysis, tumor lysis)
- Significant renal failure without established dialysis access
Observation
- K⁺ 6.0–6.4 mEq/L without ECG changes — treat and observe with repeat K⁺ in 1–2 hours
- Patients requiring insulin-glucose therapy (monitor for hypoglycemia ≥4–6 hours)
Discharge (with close follow-up)
- Mild hyperkalemia (5.0–5.9 mEq/L) without ECG changes, with identifiable and correctable cause
- K⁺ normalized after treatment with clear reversible etiology (e.g., medication-related)
- Reliable follow-up within 24–72 hours
Specialist consultation triggers
- Nephrology: New or worsening renal failure, need for dialysis, recurrent hyperkalemia on RAAS inhibitors
- Endocrinology: Suspected adrenal insufficiency
- Oncology: Tumor lysis syndrome
18. Follow Up / Return Precautions
- Follow-up timing: Recheck serum K⁺ within 24–72 hours for discharged patients; sooner if medication changes were made [5]
- Return immediately for: Palpitations, chest pain, new or worsening weakness, difficulty breathing, lightheadedness/syncope, decreased urine output
- Patient counseling:
- Review medication list — avoid NSAIDs, potassium supplements, salt substitutes
- Dietary education (ideally with renal dietitian) [8][13]
- Do not miss dialysis sessions
- Ensure adequate hydration and avoid constipation
- Expected course: Mild hyperkalemia from a reversible cause typically resolves within days with medication adjustment and dietary modification; chronic hyperkalemia in CKD/HF requires ongoing monitoring and may benefit from newer potassium binders to enable continued RAAS inhibitor therapy [15-16]
References
1. Part 10: Adult and Pediatric Special Circumstances of Resuscitation: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Cao D, Arens AM, Chow SL, et al. Circulation. 2025.
2. Potassium Disorders: Hypokalemia and Hyperkalemia. — Kim MJ, Valerio C, Knobloch GK. American Family Physician. 2023.
3. FDA Drug Label. — Updated date: 2026-01-09. Food and Drug Administration.
4. Pharmacological Interventions for the Acute Management of Hyperkalaemia in Adults. — Batterink J, Cessford TA, Taylor RA. The Cochrane Database of Systematic Reviews. 2015.
5. The Primary Care Management of Chronic Kidney Disease (CKD) (2025). — Jonathan Casey Brown DO MPH, Wendy Caesar-Gibbs RD, Cynthia Delgado MD FASN FNKF, et al Department of Veterans Affairs. 2025.
6. Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. — Sandau KE, Funk M, Auerbach A, et al. Circulation. 2017.
7. Baseline Potassium Levels and Their Association With Electrocardiograph Abnormalities in Hyperkalaemia. — Nakayama T, Mitsuno R, Azegami T, et al. Nephrology. 2025.
8. KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD. — Navaneethan SD, Bansal N, Cavanaugh KL, et al. American Journal of Kidney Diseases : The Official Journal of the National Kidney Foundation. 2025.
9. Acute Hyperkalaemia in Emergency Care: Evidence-Based Approaches. — Geldermann N, Dzimiera J, Fischer H, Christ M. Emergency Medicine Journal : EMJ. 2026.
10. FDA Orange Book. — FDA Orange Book. 2026.
11. Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review. — Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2008.
12. Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. — Ferreira JP, Butler J, Rossignol P, et al. Journal of the American College of Cardiology. 2020.
13. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. — Kidney International. 2024.
14. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD). — Michel Jadoul, Mustafa Arici, Gloria Ashuntantang, et al Kidney Disease: Improving Global Outcomes. 2022.
15. Hyperkalemia Treatment Standard. — Palmer BF, Clegg DJ. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 2024.
16. Hyperkalemia: Pathophysiology, Risk Factors and Consequences. — Hunter RW, Bailey MA. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 2019.
17. Tumor Lysis Syndrome. — Bociek RG, Lunning M. The New England Journal of Medicine. 2025.
18. The Electrocardiogram in Hyperkalemia. — Steven H. Mitchell, William J. Brady The Electrocardiagram in Emergency and Acute Care. 2023.
19. Controversies in Management of Hyperkalemia. — Long B, Warix JR, Koyfman A. The Journal of Emergency Medicine. 2018.